Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. The company's proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone GLP-1 Amylin, a combination of acting insulin glargine and rapid-acting insulin lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity, including AdoShell Islets, an ultra rapid insulin; AdOral Sema, an oral form of GLP-1 semaglutide; and AdoXLongSem, a long-lasting injectable formulation of semaglutide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
Research context
Adocia SA appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Adocia SA is currently in a long term downtrend where the price is trading 7.4% below its 200 day moving average.
From a valuation standpoint, the stock is 76.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 65.0.
Adocia SA's total revenue sank by 0.0% to $2M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 291.9% to $-7M since the same quarter in the previous year.
Based on the above factors, Adocia SA gets an overall score of 1/5.